Flex Pharma Inc (FLKS.OQ)
FLKS.OQ on NASDAQ Stock Exchange Global Market
5.21USD
25 Apr 2018
5.21USD
25 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$5.21
$5.21
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
19,617
19,617
52-wk High
$8.95
$8.95
52-wk Low
$2.68
$2.68
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.28 | -0.455 |
| Sep '17 | 0.41 | -0.537 | |
| Jun '17 | 0.34 | -0.514 | |
| Mar '17 | 0.24 | -0.490 | |
| FY 2016 | Dec '16 | 0.30 | -0.475 |
| Sep '16 | 0.60 | -0.650 | |
| Jun '16 | 0.11 | -0.706 | |
| Mar '16 | 0.00 | -0.605 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5 | 0.32 | 0.40 | 0.15 | 2.50 |
| Quarter Ending Sep-18 | 5 | 0.36 | 0.46 | 0.15 | 4.00 |
| Year Ending Dec-18 | 5 | 1.25 | 1.50 | 0.60 | 7.42 |
| Year Ending Dec-19 | 5 | 7.09 | 26.73 | 0.00 | 35.36 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 4 | -0.49 | -0.44 | -0.59 | -0.84 |
| Quarter Ending Sep-18 | 4 | -0.47 | -0.35 | -0.59 | -0.64 |
| Year Ending Dec-18 | 5 | -1.95 | -1.57 | -2.36 | -2.76 |
| Year Ending Dec-19 | 5 | -1.80 | -1.10 | -2.23 | -2.58 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 178.44 | 32.31 | |
| P/E High - Last 5 Yrs. | -- | 280.78 | 46.12 | |
| P/E Low - Last 5 Yrs. | -- | 95.19 | 24.71 | |
| Beta | -- | 0.75 | 0.79 | |
| Price to Sales (TTM) | 70.79 | 144.18 | 7.14 | |
| Price to Book (MRQ) | 3.19 | 18.80 | 4.88 | |
| Price to Tangible Book (MRQ) | 3.10 | 23.34 | 6.49 | |
| Price to Cash Flow (TTM) | -- | 117.05 | 24.37 | |
| % Owned Institutions | 46.90 | 11.29 | 2.32 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.29 | 1.58 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 0.78 | |
| Dividend 5 Year Growth Rate | -- | 1.96 | 4.08 | |
| Payout Ratio(TTM) | -- | 9.23 | 21.09 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -5.38 | 103.37 | 9.18 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 26.11 | 79.40 | 11.01 | |
| Sales - 5 Yr. Growth Rate | -- | 33.48 | 8.23 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 4.27 | -66.76 | 23.62 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 18.09 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 46.41 | 10.39 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 44.90 | 10.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 5.83 | 1.70 | 2.52 |
| Current Ratio (MRQ) | 5.91 | 5.99 | 3.58 |
| LT Debt to Equity (MRQ) | 0.00 | 23.56 | 11.61 |
| Total Debt to Equity (MRQ) | 0.00 | 26.01 | 14.31 |
| Interest Coverage (TTM) | -- | -183.16 | 30.88 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 60.26 | 31.78 | 54.20 | |
| Gross Margin - 5 Yr. Avg. | -- | 55.29 | 52.34 | |
| EBITD Margin (TTM) | -2,699.18 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -149.45 | 15.90 | |
| Operating Margin (TTM) | -2,724.65 | -587.01 | 3.62 | |
| Operating Margin - 5 Yr. Avg. | -- | -161.52 | 11.17 | |
| Pre-Tax Margin (TTM) | -2,701.74 | -560.40 | 4.27 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -168.41 | 11.48 | |
| Net Profit Margin (TTM) | -2,701.74 | -548.74 | 0.90 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -168.67 | 7.81 | |
| Effective Tax Rate (TTM) | -- | -0.45 | 31.67 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.02 | 24.29 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 63,725 | 23,441,753 | 786,924,448 | |
| Net Income/Employee (TTM) | -1,721,683 | 684,681 | 92,306,248 | |
| Receivable Turnover (TTM) | 112.94 | 6.13 | 5.48 | |
| Inventory Turnover (TTM) | 1.14 | 2.39 | 3.46 | |
| Asset Turnover (TTM) | 0.03 | 0.40 | 0.87 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -70.12 | -0.78 | 10.35 | |
| Return on Assets - 5 Yr. Avg. | -- | 0.53 | 11.38 | |
| Return on Investment (TTM) | -77.84 | -0.73 | 12.97 | |
| Return on Investment - 5 Yr. Avg. | -- | 3.99 | 14.74 | |
| Return on Equity (TTM) | -77.88 | -2.77 | 14.84 | |
| Return on Equity - 5 Yr. Avg. | -- | -0.21 | 16.08 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 26.11 | -- | -- |
| EPS (TTM) % | 18.00 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Flex Pharma Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis
- BRIEF-Flex Pharma Reports Q4 Loss Per Share $0.46
- BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business
- BRIEF-Flex Pharma Inc - Completed Enrollment In Its Phase 2 Exploratory Spasticity Study In Multiple Sclerosis With Approximately 50 Patients In Australia
- BRIEF-Flex Pharma Q3 loss per share $0.54
Institutional Holders
| % Shares Owned: | 46.90% |
| # of Holders: | 47 |
| Total Shares Held: | 8,435,627 |
| 3 Mo. Net Change: | 3,530 |
| # New Positions: | 1 |
| # Closed Positions: | 0 |
| # Increased Positions: | 2 |
| # Reduced Positions: | 0 |
| # Net Buyers: | 2 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.